Trial Review

The ANZCTR website is back online for trial registration and updates. We apologise for any inconvenience caused while the site was inactive.

Please note that the ANZCTR will be unattended from Friday 18th April until Tuesday 22nd April due to the Easter long weekend. Submissions and updates will not be processed during that time.



Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements. New passwords must include at least one lowercase letter, one uppercase letter, one number and one special character (e.g. !#$%&@).
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04308681




Registration number
NCT04308681
Ethics application status
Date submitted
12/03/2020
Date registered
16/03/2020
Date last updated
24/02/2025

Titles & IDs
Public title
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
Scientific title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis
Secondary ID [1] 0 0
2019-003992-21
Secondary ID [2] 0 0
IM027-040
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pulmonary Fibrosis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - BMS-986278 Placebo
Treatment: Drugs - BMS-986278

Experimental: IPF Dose 1 + Post Treatment Follow-up or OTE - IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension)

Experimental: IPF Dose 2 + Post Treatment Follow-up or OTE -

Placebo comparator: IPF Placebo + Post Treatment Follow-up or OTE -

Experimental: PF-ILD Dose 1 + Post Treatment Follow-up or OTE - PF-ILD (Progressive Fibrotic Interstitial Lung Disease)

Experimental: PF-ILD Dose 2 + Post Treatment Follow-up or OTE -

Placebo comparator: PF-ILD Placebo + Post Treatment Follow-up or OTE -


Other interventions: BMS-986278 Placebo
Specified Dose on Specified Days

Treatment: Drugs: BMS-986278
Specified Dose on Specified Days
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF Participants
Timepoint [1] 0 0
From baseline (first dose) up to week 26
Secondary outcome [1] 0 0
The Number of Participants Experiencing Adverse Events (AEs)
Timepoint [1] 0 0
From first dose up to 30 days after last dose during the main study treatment phase
Secondary outcome [2] 0 0
The Number of Participants Experiencing Serious Adverse Events (SAEs)
Timepoint [2] 0 0
From first dose up to 30 days after last dose during the main study treatment phase
Secondary outcome [3] 0 0
The Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
Timepoint [3] 0 0
From first dose up to 30 days after last dose during the main study treatment phase
Secondary outcome [4] 0 0
The Number of Participants Who Died Due to Adverse Events (AEs)
Timepoint [4] 0 0
From first dose up to 30 days after last dose during the main study treatment phase
Secondary outcome [5] 0 0
Maximum Concentration (Cmax)
Timepoint [5] 0 0
On Day 1 and Week 4 (Day 29)
Secondary outcome [6] 0 0
Time to Maximum Concentration (Tmax)
Timepoint [6] 0 0
On Day 1 and Week 4 (Day 29)
Secondary outcome [7] 0 0
Area Under Curve (AUC0-8)
Timepoint [7] 0 0
On Day 1 and Week 4 (Day 29)
Secondary outcome [8] 0 0
Concentration Trough (Ctrough)
Timepoint [8] 0 0
On Week 4 (Day 29) and Week 12 (Day 85)
Secondary outcome [9] 0 0
The Number of Participants Experiencing Electrocardiogram (ECG) Abnormalities
Timepoint [9] 0 0
At Week 26
Secondary outcome [10] 0 0
Change From Baseline in Vital Sign Measurements
Timepoint [10] 0 0
At baseline and Week 26
Secondary outcome [11] 0 0
Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in PF-ILD Participants
Timepoint [11] 0 0
At baseline and Week 26
Secondary outcome [12] 0 0
The Number of Participants With = 10% Absolute Decline in ppFVC (%)
Timepoint [12] 0 0
At Weeks 4, 8, 12, 16, 20, and 26
Secondary outcome [13] 0 0
The Number of Participants With 0% Change in ppFVC (%)
Timepoint [13] 0 0
Weeks 4, 8, 12, 16, 20, and 26
Secondary outcome [14] 0 0
Time to First Occurrence = 10% Absolute Decline in ppFVC (%)
Timepoint [14] 0 0
From first dose up to the first occurrence of = 10% absolute decline in ppFVC
Secondary outcome [15] 0 0
Absolute Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC)
Timepoint [15] 0 0
From baseline up to Weeks 4, 8, 12, 16, 20, and 26
Secondary outcome [16] 0 0
Absolute Change From Baseline in Forced Vital Capacity (FVC)
Timepoint [16] 0 0
From baseline up to Weeks 4, 8, 12, 16, 20, and 26
Secondary outcome [17] 0 0
Absolute Change From Baseline in Single Breath Diffusing Capacity of Carbon Monoxide (DLCO SB)
Timepoint [17] 0 0
From baseline up to Week 26
Secondary outcome [18] 0 0
Absolute Change From Baseline in Percent Predicted Single Breath Diffusing Capacity of Carbon Monoxide (ppDLCO SB)
Timepoint [18] 0 0
From baseline up to Week 26
Secondary outcome [19] 0 0
Absolute Change From Baseline in Walking Endurance/Distance
Timepoint [19] 0 0
From baseline up to Week 26
Secondary outcome [20] 0 0
Time to First Acute Exacerbation
Timepoint [20] 0 0
From the first dose up to the day of the first acute exacerbation or Week 26, whichever comes first
Secondary outcome [21] 0 0
The Number of Participants Experiencing Acute Exacerbation
Timepoint [21] 0 0
From the first dose up to the day of the first acute exacerbation or Week 26, whichever comes first

Eligibility
Key inclusion criteria
For the idiopathic pulmonary fibrosis (IPF) Cohort

* Diagnosis of IPF within 7 years of screening
* Female and males = 40 years of age

For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort

* Evidence of progressive ILD within the 24 months before screening
* Female and male = 21 years of age.
Minimum age
21 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Women of childbearing potential (WOCBP)
* Active Smokers
* Current malignancy or previous malignancy up to 5 years prior to screening
* History of allergy to BMS-986278 or related compounds

Other protocol-defined inclusion/exclusion criteria apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/07/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
22/09/2023
Sample size
Target
Accrual to date
Final
403
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Local Institution - 0045 - Camperdown
Recruitment hospital [2] 0 0
Local Institution - 0025 - Westmead
Recruitment hospital [3] 0 0
Local Institution - 0026 - Brisbane
Recruitment hospital [4] 0 0
Local Institution - 0046 - Greenslopes
Recruitment hospital [5] 0 0
Local Institution - 0022 - Adelaide
Recruitment hospital [6] 0 0
Local Institution - 0023 - Heidelberg
Recruitment hospital [7] 0 0
Local Institution - 0021 - Murdoch
Recruitment hospital [8] 0 0
Local Institution - 0044 - Nedlands
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4032 - Brisbane
Recruitment postcode(s) [4] 0 0
4120 - Greenslopes
Recruitment postcode(s) [5] 0 0
5000 - Adelaide
Recruitment postcode(s) [6] 0 0
3084 - Heidelberg
Recruitment postcode(s) [7] 0 0
6150 - Murdoch
Recruitment postcode(s) [8] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Ohio
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Virginia
Country [16] 0 0
Argentina
State/province [16] 0 0
Distrito Federal
Country [17] 0 0
Argentina
State/province [17] 0 0
Santa FE
Country [18] 0 0
Argentina
State/province [18] 0 0
Tucuman
Country [19] 0 0
Argentina
State/province [19] 0 0
Buenos AIres
Country [20] 0 0
Argentina
State/province [20] 0 0
Buenos Aires
Country [21] 0 0
Argentina
State/province [21] 0 0
Mendoza
Country [22] 0 0
Belgium
State/province [22] 0 0
Brussels
Country [23] 0 0
Belgium
State/province [23] 0 0
Leuven
Country [24] 0 0
Belgium
State/province [24] 0 0
Liège
Country [25] 0 0
Brazil
State/province [25] 0 0
RIO Grande DO SUL
Country [26] 0 0
Brazil
State/province [26] 0 0
SAO Paulo
Country [27] 0 0
Brazil
State/province [27] 0 0
Sao Paulo
Country [28] 0 0
Canada
State/province [28] 0 0
British Columbia
Country [29] 0 0
Canada
State/province [29] 0 0
Ontario
Country [30] 0 0
Canada
State/province [30] 0 0
Quebec
Country [31] 0 0
Chile
State/province [31] 0 0
Maule
Country [32] 0 0
Chile
State/province [32] 0 0
Valparaiso
Country [33] 0 0
China
State/province [33] 0 0
Beijing
Country [34] 0 0
China
State/province [34] 0 0
Hubei
Country [35] 0 0
China
State/province [35] 0 0
Shanghai
Country [36] 0 0
France
State/province [36] 0 0
Bobigny
Country [37] 0 0
France
State/province [37] 0 0
Bron
Country [38] 0 0
France
State/province [38] 0 0
Dijon
Country [39] 0 0
France
State/province [39] 0 0
Marseille
Country [40] 0 0
France
State/province [40] 0 0
Paris
Country [41] 0 0
France
State/province [41] 0 0
Rennes
Country [42] 0 0
France
State/province [42] 0 0
Toulouse
Country [43] 0 0
Germany
State/province [43] 0 0
Niedersachsen
Country [44] 0 0
Germany
State/province [44] 0 0
Essen
Country [45] 0 0
Germany
State/province [45] 0 0
Freiburg
Country [46] 0 0
Germany
State/province [46] 0 0
Grosshansdorf
Country [47] 0 0
Germany
State/province [47] 0 0
Heidelberg
Country [48] 0 0
Germany
State/province [48] 0 0
Munich
Country [49] 0 0
Germany
State/province [49] 0 0
Stuttgart
Country [50] 0 0
Israel
State/province [50] 0 0
Tel-Aviv
Country [51] 0 0
Israel
State/province [51] 0 0
Haifa
Country [52] 0 0
Israel
State/province [52] 0 0
Jerusalem
Country [53] 0 0
Israel
State/province [53] 0 0
Petah Tikva
Country [54] 0 0
Israel
State/province [54] 0 0
Ramat Gan
Country [55] 0 0
Italy
State/province [55] 0 0
Catania
Country [56] 0 0
Italy
State/province [56] 0 0
Modena
Country [57] 0 0
Italy
State/province [57] 0 0
Monza
Country [58] 0 0
Italy
State/province [58] 0 0
Roma
Country [59] 0 0
Japan
State/province [59] 0 0
Aichi
Country [60] 0 0
Japan
State/province [60] 0 0
Fukushima
Country [61] 0 0
Japan
State/province [61] 0 0
Hokkaido
Country [62] 0 0
Japan
State/province [62] 0 0
Hyogo
Country [63] 0 0
Japan
State/province [63] 0 0
Kanagawa
Country [64] 0 0
Japan
State/province [64] 0 0
Osaka
Country [65] 0 0
Japan
State/province [65] 0 0
Shimane
Country [66] 0 0
Japan
State/province [66] 0 0
Shizuoka
Country [67] 0 0
Japan
State/province [67] 0 0
Tokyo
Country [68] 0 0
Japan
State/province [68] 0 0
Kumamoto
Country [69] 0 0
Japan
State/province [69] 0 0
Nagasaki
Country [70] 0 0
Japan
State/province [70] 0 0
Saitama
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Seoul
Country [72] 0 0
Mexico
State/province [72] 0 0
Distrito Federal
Country [73] 0 0
Mexico
State/province [73] 0 0
Nuevo Leon
Country [74] 0 0
Mexico
State/province [74] 0 0
Nuevo LEON
Country [75] 0 0
Mexico
State/province [75] 0 0
Oaxaca
Country [76] 0 0
Spain
State/province [76] 0 0
Barcelona
Country [77] 0 0
Spain
State/province [77] 0 0
L'Hospitalet de Llobregat
Country [78] 0 0
Spain
State/province [78] 0 0
Madrid
Country [79] 0 0
Spain
State/province [79] 0 0
Marbella Málaga
Country [80] 0 0
Spain
State/province [80] 0 0
Pozuelo de Alarcon
Country [81] 0 0
Spain
State/province [81] 0 0
Santander
Country [82] 0 0
Taiwan
State/province [82] 0 0
Kaohsiung
Country [83] 0 0
Taiwan
State/province [83] 0 0
Taipei
Country [84] 0 0
United Kingdom
State/province [84] 0 0
Cambridge
Country [85] 0 0
United Kingdom
State/province [85] 0 0
Edinburgh
Country [86] 0 0
United Kingdom
State/province [86] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT04308681